


IMMUNOGEN

ImmunoGen, Inc.
Investor Relations Department
830 Winter Street
Waltham, MA 02451
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: IMGN

Last Trade:	7.00
Trade Time:	4:00 PM ET Jun 28, 2017
Change:	0.46  (+7.034%)
Day Range	6.45 - 7.10
52-Week Range	1.51 - 7.00
Volume	4,097,439

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyca[®], in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jun 26, 2017

[ImmunoGen Presents Data from Phase I Study of IMGN779 in Acute Myeloid Leukemia](#)

May 30, 2017

[ImmunoGen and Sanofi Amend License Agreements](#)

May 24, 2017

[ImmunoGen Announces Webcast of Presentation at the Jefferies Global Healthcare Conference](#)

May 23, 2017

[Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen](#)

May 17, 2017

[ImmunoGen Announces New Clinical Data with Mirvetuximab Soravtansine in Ovarian Cancer to be Presented at 2017 ASCO Annual Meeting](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Aug 25, 2016

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)

Nov 4, 2016

[Quarterly Report \(10-Q\)](#)

May 4, 2016

[Quarterly Report \(10-Q\)](#)